copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Homepage - RAPT Therapeutics RAPT Therapeutics is a clinical-stage biopharmaceutical company driven by a bold mission—to treat inflammatory diseases and conquer cancer in our lifetime Our cutting-edge science is fully focused on developing oral therapeutics that intelligently target key drivers of the immune system to transform the treatment of inflammation and cancer, and improve and empower countless lives Join […]
Pipeline - RAPT Therapeutics RAPT Therapeutics is focused on the development of oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology Utilizing our proprietary discovery engine, we are developing highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases
About Us - RAPT Therapeutics RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and cancer Utilizing our proprietary drug discovery and development engine, we develop highly selective small molecules that are designed to modulate the critical
Press Releases - RAPT Therapeutics April 09 | 2024 RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients March 07 | 2024 RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results March 05 | 2024
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in . . . RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively The company is also pursuing a range of targets that are in the discovery stage of development
Press Releases - RAPT Therapeutics, Inc. RAPT Therapeutics Reports First Quarter 2024 Financial Results Company maintains solid cash position of $141 6 million SOUTH SAN FRANCISCO, Calif , May 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small
RAPT Therapeutics Announces Publication of Phase 1a 1b Clinical Trial . . . RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology
RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial . . . RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively RAPT is also pursuing a range of targets that are in the discovery stage of development Forward-Looking Statements
Publications - RAPT Therapeutics Publications - RAPT Therapeutics Scientific Publications Zelnecirnon (RPT193) Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study Allergy, November 2023 View paper (PDF) Treatment with the Oral CCR4 Antagonist RPT193 Results in Meaningful Changes in Cutaneous Biomarkers Detected by
Zelnecirnon (RPT193) - RAPT Therapeutics Explore how zelnecirnon (RPT193)—designed to block CCR4—may potentially impact inflammatory disorders including eczema (atopic dermatitis) and asthma Zelnecirnon is an orally-administered small molecule CCR4 antagonist that blocks the recruitment of inflammatory immune cells, known as Th2 cells, which are clinically implicated in a broad range of inflammatory disorders Although there are